Literature DB >> 31164371

Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma.

Ali Amin-Mansour1, Suzanne George2, Stefano Sioletic3, Scott L Carter1, Mara Rosenberg1, Amaro Taylor-Weiner1, Chip Stewart1, Aaron Chevalier1, Sara Seepo1, Adam Tracy1, Gad Getz1, Jason L Hornick3, Marisa R Nucci3, Bradley Quade3, George D Demetri2,4, Chandrajit P Raut5, Levi A Garraway1,2,6, Eliezer M Van Allen7,2,6, Andrew J Wagner8.   

Abstract

PURPOSE: Leiomyosarcoma and liposarcoma are common subtypes of soft tissue sarcoma (STS). Patients with metastatic leiomyosarcoma or dedifferentiated liposarcoma (DDLPS) typically have worse outcomes compared with localized leiomyosarcoma or well-differentiated liposarcoma (WDLPS). A better understanding of genetic changes between primary/metastatic leiomyosarcoma and between WDLPS/DDLPS may provide insight into their genetic evolution. EXPERIMENTAL
DESIGN: We interrogated whole-exome sequencing (WES) from "trios" of normal tissue, primary tumor, and metastatic tumor from individual patients with leiomyosarcoma (n = 9), and trios of normal tissue, well-differentiated tumor, and dedifferentiated tumor from individual patients with liposarcoma (n = 19). Specifically, we performed mutational, copy number, and tumor evolution analyses on these cohorts and compared patterns among leiomyosarcoma and liposarcoma trios.
RESULTS: Leiomyosarcoma cases harbored shared drivers through a typical parent/child relationship where the metastatic tumor was derived from the primary tumor. In contrast, while all liposarcoma cases shared the characteristic focal chromosome 12 amplicon, most paired liposarcoma cases did not share additional mutations, suggesting a divergent evolutionary pattern from a common precursor. No highly recurrent genomic alterations from WES were identified that could be implicated as driving the progression of disease in either sarcoma subtype.
CONCLUSIONS: From a genomic perspective, leiomyosarcoma metastases contain genetic alterations that are also found in primary tumors. WDLPS and DDLPS, however, appear to divergently evolve from a common precursor harboring 12q amplification, rather than as a transformation to a higher-grade tumor. Further efforts to identify specific drivers of these distinct evolutionary patterns may inform future translational and clinical research in STS. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2019        PMID: 31164371      PMCID: PMC7341441          DOI: 10.1158/1078-0432.CCR-19-0271

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

1.  The architecture and evolution of cancer neochromosomes.

Authors:  Dale W Garsed; Owen J Marshall; Vincent D A Corbin; Arthur Hsu; Leon Di Stefano; Jan Schröder; Jason Li; Zhi-Ping Feng; Bo W Kim; Mark Kowarsky; Ben Lansdell; Ross Brookwell; Ola Myklebost; Leonardo Meza-Zepeda; Andrew J Holloway; Florence Pedeutour; K H Andy Choo; Michael A Damore; Andrew J Deans; Anthony T Papenfuss; David M Thomas
Journal:  Cancer Cell       Date:  2014-11-10       Impact factor: 31.743

2.  Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

Authors:  Dan A Landau; Scott L Carter; Petar Stojanov; Aaron McKenna; Kristen Stevenson; Michael S Lawrence; Carrie Sougnez; Chip Stewart; Andrey Sivachenko; Lili Wang; Youzhong Wan; Wandi Zhang; Sachet A Shukla; Alexander Vartanov; Stacey M Fernandes; Gordon Saksena; Kristian Cibulskis; Bethany Tesar; Stacey Gabriel; Nir Hacohen; Matthew Meyerson; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  Cell       Date:  2013-02-14       Impact factor: 41.582

3.  Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas.

Authors:  Barry S Taylor; Penelope L DeCarolis; Christina V Angeles; Fabienne Brenet; Nikolaus Schultz; Cristina R Antonescu; Joseph M Scandura; Chris Sander; Agnes J Viale; Nicholas D Socci; Samuel Singer
Journal:  Cancer Discov       Date:  2011-12       Impact factor: 39.397

Review 4.  Liposarcomas.

Authors:  Joern Henze; Sebastian Bauer
Journal:  Hematol Oncol Clin North Am       Date:  2013-10       Impact factor: 3.722

5.  MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors.

Authors:  Caroline M M Gits; Patricia F van Kuijk; Moniek B E Jonkers; Antonius W M Boersma; Marcel Smid; Wilfred F van Ijcken; Jean-Michel Coindre; Fréderic Chibon; Cornelis Verhoef; Ron H J Mathijssen; Michael A den Bakker; Jaap Verweij; Stefan Sleijfer; Erik A C Wiemer
Journal:  Int J Cancer       Date:  2014-01-16       Impact factor: 7.396

6.  A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries.

Authors:  Sheila Fisher; Andrew Barry; Justin Abreu; Brian Minie; Jillian Nolan; Toni M Delorey; Geneva Young; Timothy J Fennell; Alexander Allen; Lauren Ambrogio; Aaron M Berlin; Brendan Blumenstiel; Kristian Cibulskis; Dennis Friedrich; Ryan Johnson; Frank Juhn; Brian Reilly; Ramy Shammas; John Stalker; Sean M Sykes; Jon Thompson; John Walsh; Andrew Zimmer; Zac Zwirko; Stacey Gabriel; Robert Nicol; Chad Nusbaum
Journal:  Genome Biol       Date:  2011-01-04       Impact factor: 13.583

7.  Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.

Authors:  Netta Mäkinen; Mervi Aavikko; Tuomas Heikkinen; Minna Taipale; Jussi Taipale; Riitta Koivisto-Korander; Ralf Bützow; Pia Vahteristo
Journal:  PLoS Genet       Date:  2016-02-18       Impact factor: 5.917

8.  DeTiN: overcoming tumor-in-normal contamination.

Authors:  Amaro Taylor-Weiner; Chip Stewart; Thomas Giordano; Mendy Miller; Mara Rosenberg; Alyssa Macbeth; Niall Lennon; Esther Rheinbay; Dan-Avi Landau; Catherine J Wu; Gad Getz
Journal:  Nat Methods       Date:  2018-06-25       Impact factor: 28.547

9.  Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.

Authors:  A H Beck; C-H Lee; D M Witten; B C Gleason; B Edris; I Espinosa; S Zhu; R Li; K D Montgomery; R J Marinelli; R Tibshirani; T Hastie; D M Jablons; B P Rubin; C D Fletcher; R B West; M van de Rijn
Journal:  Oncogene       Date:  2009-11-09       Impact factor: 9.867

10.  Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation.

Authors:  Maura Costello; Trevor J Pugh; Timothy J Fennell; Chip Stewart; Lee Lichtenstein; James C Meldrim; Jennifer L Fostel; Dennis C Friedrich; Danielle Perrin; Danielle Dionne; Sharon Kim; Stacey B Gabriel; Eric S Lander; Sheila Fisher; Gad Getz
Journal:  Nucleic Acids Res       Date:  2013-01-08       Impact factor: 16.971

View more
  7 in total

Review 1.  Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.

Authors:  Jun Lu; David Wood; Evan Ingley; Sulev Koks; Daniel Wong
Journal:  Mol Biol Rep       Date:  2021-04-24       Impact factor: 2.316

2.  Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma.

Authors:  Irene Alessandrini; Stefano Percio; Eisa Naghshineh; Valentina Zuco; Silvia Stacchiotti; Alessandro Gronchi; Sandro Pasquali; Nadia Zaffaroni; Marco Folini
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

3.  Identification of somatic alterations in lipoma using whole exome sequencing.

Authors:  Deepika Kanojia; Pushkar Dakle; Anand Mayakonda; Rajeev Parameswaran; Mark E Puhaindran; Victor Lee Kwan Min; Vikas Madan; Phillip Koeffler
Journal:  Sci Rep       Date:  2019-10-07       Impact factor: 4.379

4.  Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.

Authors:  Valentina Zuco; Sandro Pasquali; Silvia Stacchiotti; Nadia Zaffaroni; Monica Tortoreto; Silvia Brich; Stefano Percio; Gian Paolo Dagrada; Chiara Colombo; Roberta Sanfilippo; Calogero Lauricella; Mrinal Gounder; Rihan El Bezawy; Marta Barisella; Angelo Paolo Dei Tos; Paolo Giovanni Casali; Alessandro Gronchi
Journal:  J Exp Clin Cancer Res       Date:  2021-03-01

5.  Development and validation of a novel prognostic model for long-term overall survival in liposarcoma patients: a population-based study.

Authors:  Shuai Cao; Jie Li; Kai Yang; Jun Zhang; Jiawei Xu; Chaoshuai Feng; Haopeng Li
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

6.  Differential whole-genome doubling and homologous recombination deficiencies across breast cancer subtypes from the Taiwanese population.

Authors:  Chia-Hsin Wu; Chia-Shan Hsieh; Yo-Cheng Chang; Chi-Cheng Huang; Hsien-Tang Yeh; Ming-Feng Hou; Yuan-Chiang Chung; Shih-Hsin Tu; King-Jen Chang; Amrita Chattopadhyay; Liang-Chuan Lai; Tzu-Pin Lu; Yung-Hua Li; Mong-Hsun Tsai; Eric Y Chuang
Journal:  Commun Biol       Date:  2021-09-09

7.  Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.

Authors:  Mrinal Gounder; Albiruni R Abdul Razak; Adrienne M Gilligan; Hoyee Leong; Xiwen Ma; Neeta Somaiah; Sant P Chawla; Javier Martin-Broto; Giovanni Grignani; Scott M Schuetze; Bruno Vincenzi; Andrew J Wagner; Bartosz Chmielowski; Robin L Jones; Jatin Shah; Sharon Shacham; Michael Kauffman; Richard F Riedel; Steven Attia
Journal:  Future Oncol       Date:  2021-04-15       Impact factor: 3.674

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.